Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-KAAG1 antibody-drug conjugate ADCT-901

An antibody-drug conjugate (ADC) composed of 3A4, a humanized monoclonal antibody directed against human kidney associated antigen 1 (KAAG1; RU2) and conjugated, through a cathepsin-cleavable linker, to SG3199, a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-KAAG1 ADC ADCT-901, the 3A4 moiety targets and binds to KAAG1, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage by cathepsin, free PBD is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing KAAG1-expressing cancer cells. KAAG1, overexpressed by certain tumor cell types, plays a key role in tumor cell proliferation. Its expression on healthy tissue is very restricted.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC ADCT-901
anti-KAAG1 ADC ADCT-901
antibody-drug conjugate ADCT-901
Code name:ADCT 901
ADCT-901
ADCT901
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search